ROIV
Roivant Sciences Ltd.
1W: -1.6%
1M: -3.1%
3M: +20.7%
YTD: +24.8%
1Y: +152.7%
3Y: +214.2%
5Y: +179.0%
$27.36
+0.49 (+1.82%)
After Hours: $27.50 (+0.14, +0.51%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$19.6B
52W Range8.73-30.33
Volume3,062,784
Avg Volume6,455,369
Beta1.21
Dividend—
Analyst Ratings
Company Info
CEOMatthew Gline
Employees908
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-08
Websiteroivant.com
11-12 St. James's Square
London SW1Y 4LB
GB
London SW1Y 4LB
GB
44 2074 003 347
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest News
Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna gains as Arbutus/ Genevant settlement removes major financial risk
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pulik Richard | F-InKind | 1,546 | $27.70 | 2026-03-20 |
| Humes Jennifer | F-InKind | 14,526 | $27.70 | 2026-03-20 |
| Venker Eric | M-Exempt | 200,000 | $3.85 | 2026-03-17 |
| Venker Eric | S-Sale | 200,000 | $28.24 | 2026-03-17 |
| Venker Eric | M-Exempt | 200,000 | $3.85 | 2026-03-17 |